Can Celgene’s Most Important Drugs Keep Growing?

Can Celgene’s Most Important Drugs Keep Growing?

Source: 
Motley Fool
snippet: 

Celgene Corp. (NASDAQ:CELG) markets four billion-dollar blockbuster medicines, but only two were behind its stellar sales and profit performance in the second quarter. Sales of Revlimid grew 21% to $2.4 billion, and Pomalyst sales increased 30% to $507 million. Can these multiple myeloma drugs continue to deliver growth for Celgene's investors?